Pubblicazioni

Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients

2021 - ANNALS OF HEMATOLOGY

Scalzulli, E.; Caocci, G.; Efficace, F.; Rizzo, L.; Colafigli, G.; Di Prima, A.; Pepe, S.; Fegatelli, D. A.; Carmosino, I.; Diverio, D.; Latagliata, R.; La Nasa, G.; Martelli, M.; Foa, R.; Breccia, M.

Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience

2020 - ANNALS OF HEMATOLOGY

Pepe, S.; Scalzulli, E.; Colafigli, G.; Di Prima, A.; Diverio, D.; Mancini, M.; Latagliata, R.; Martelli, M.; Foa, R.; Breccia, M.

Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy

2018 - ANNALS OF HEMATOLOGY

Cicconi, L; Breccia, M; Franceschini, L; Latagliata, R; Molica, M; Divona, M; Diverio, D; Rizzo, M; Ottone, T; Iaccarino, L; Alfonso, V; Foa, R; Voso, Mt; Lo-Coco, F

Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies

2015 - ANNALS OF HEMATOLOGY

Oosterveld, M; Suciu, S; Muus, P; Germing, U; Delforge, M; Belhabri, A; Aul, C; Selleslag, D; Ferrant, A; Marie, Jp; Amadori, S; Jehn, U; Mandelli, F; Hess, U; HellstrÃ¶m-Lindberg, E; Cakmak-Wollgast, S; Vignetti, M; Labar, B; Willemze, R; de Witte, T.